Home
Conditions
CD20 Positive

Clinical trial condition

CD20 Positive

Explore clinical trials studying CD20 Positive. Study availability and eligibility vary by location and protocol.

10 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

CD20 Positive trial results

Active, not recruiting

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

NCT01959698

Conditions: CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Active, not recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04007029

Conditions: CD19 Positive, CD20 Positive, Chronic Disease, +33 more
Locations: UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Active, not recruiting

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT03946878

Conditions: Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, +16 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01880567

Conditions: CCND1 Positive, CCND2 Positive, CCND3 Positive, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

NCT02532257

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, +17 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT01363128

Conditions: Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, +24 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

NCT00439556

Conditions: CD20 Positive, Hematologic Diseases, Hematologic Neoplasms, +11 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

NCT00880815

Conditions: CD20 Positive, Chronic Disease, Chronic Lymphocytic Leukemia, +28 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

NCT01729806

Conditions: CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

USC / Norris Comprehensive Cancer Center Los Angeles, California, United States

University of California Davis Comprehensive Cancer Center Sacramento, California, United States

City of Hope South Pasadena South Pasadena, California, United States

View Trial Details

Completed

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02219737

Conditions: CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Memorial Sloan-Kettering Cancer Center New York, United States

View Trial Details

CD20 Positive

CD20 Positive trial results

Related conditions